Roche’s KRAS Lung Cancer Drug Clears a Key Comparison, Putting the Targeted Therapy Standard at Risk of Being Rewritten

For lung cancer patients with a KRAS G12C mutation, targeted therapy is no longer an empty field. But “having a drug available” and “which drug can become the new standard” remain two different questions. The significance of the positive late-stage clinical trial results reported for Roche’s experimental drug divarasib lies precisely here: it is not simply being compared with placebo or chemotherapy, but is being put up against an approved KRAS drug.

STAT reported that the news has led divarasib to be viewed as a new benchmark in the field of KRAS-driven lung cancer. According to Roche’s external statements, the late-stage trial enrolled previously treated patients with advanced non-small cell lung cancer and compared divarasib with currently marketed KRAS G12C inhibitors. The company said divarasib met the trial goals for both progression-free survival and overall survival, and that no new safety signals were observed.

KRAS was long seen as a cancer driver gene that was difficult to drug. It was not until covalent inhibitors targeting the G12C mutation site emerged that this group of patients gained a clear oral targeted option. Amgen’s sotorasib and adagrasib, developed by Mirati and later acquired by Bristol Myers Squibb, have successively opened the market. If divarasib can prove better clinical outcomes in a head-to-head trial, the competition will shift from “who launched first” to “who can help patients live longer and keep disease controlled for longer.”

However, the data publicly available at this stage remain relatively summary-level. Key questions include how many patients were actually enrolled in the trial, whether baseline risks were balanced between the two groups, how large the survival benefit was, how discontinuation rates and adverse events such as liver toxicity were distributed, and whether the results are sufficiently mature. Without these details, the “new standard” still looks more like a strong signal ahead of regulatory submission than a completed rewriting of clinical practice.

Background Context

Divarasib had already gained visibility after positive results were reported from a phase 3 trial. This time, the focus has shifted further to whether it can translate clinical advantage into approval and a position in guidelines. For Roche, this is not just about adding an oncology product line, but also about seeking differentiation in the KRAS targeted drug race: with the same mutation and the same treatment setting, if benefit can be demonstrated with a more rigorous comparator, both commercial and medical value would be amplified.

The next milestones will be publication of the full data and drug regulatory reviews in various countries. If regulators accept this head-to-head evidence, divarasib could become a new oral option for KRAS G12C-mutated lung cancer after prior treatment. If the data show that benefit is concentrated in specific groups, clinical use may depend more on stratification by genetic co-mutations, prior treatment, and tolerability. What can be said now is that KRAS lung cancer treatment has entered a second phase: the question is no longer only whether the target can be hit, but whether, after hitting it, the course of disease can truly be changed.